The Brain Imaging workshop is almost here.
Syntermed is ready to show the latest tools to help position your practice for success.
Released this past year, NeuroQ version 3.7 uses the standardized region of interest (ROI) method to analyze SPECT data.
NeuroQ provides ultimate confidence in the differential diagnosis of dementia, which makes a major impact on dementia therapy.
The NeuroQ method for regional quantification of PET scans has been FDA-cleared for analysis of both FDG and amyloid imaging data.
Dr. Daniel Silverman, MD, PhD
Head, Neuronuclear Imaging Section
Ahmanson Translational Imaging Division
Director, Brain Wellness and PET Consultation Services
Professor, Department of Molecular and Medical Pharmacology
Executive Committee, UCLA Alzheimer's Disease Research Center
David Geffen School of Medicine, University of California, Los Angeles
Dr. Silverman is Head of the Neuronuclear Imaging Section of the Ahmanson Translational Imaging Division at University of California, Los Angeles. He also serves as Professor in the Department of Molecular and Medical Pharmacology, and on the Executive Committee of the UCLA Alzheimer’s Disease Center. Dr. Silverman obtained his PhD in Biological Chemistry at Harvard University, and completed postdoctoral research training in Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He received his MD from The Ohio State University College of Medicine, and subsequently completed post-MD training at UCLA, before being board-certified by both the American Board of Internal Medicine and the American Board of Nuclear Medicine. Dr. Silverman’s main research areas involve: 1) neuronuclear imaging, especially to explore cognitive function and dysfunction, associated with factors such as Alzheimer’s and other neurodegenerative diseases, cancer and chemotherapy, exogenous or endogenous hormonal status, and mood; and 2) the evaluation and management of neoplastic disease (especially breast cancer and lymphoma).
David Cooke, MSEE
Director of Clinical Applications, Syntermed
Mr. Cooke, Director of Clinical Applications, has been Syntermed’s primary developer of NeuroQ since its inception and also oversees the clinical collaboration between Syntermed and UCLA for new product features and enhancements. Mr. Cooke is also part of the R&D team at Emory University responsible for the development of the Emory Cardiac Toolbox. Mr. Cooke obtained his BEE from Auburn University and his MSEE from Georgia Institue of Technology.
Participants will gain an understanding of the basic aspects of PET methodology, clinical applications of PET, how such uses compare with similar information acquired through SPECT brain imaging, and how these approaches can contribute to overall patient management. A demonstration of NeuroQ (v3.7) will be also be given including several case studies using NeuroQ. If you are currently performing brain PET studies, or considering doing so, this is a unique opportunity to learn from one of the leading experts for Brain Imaging.
07:30 AM Registration and Continental Breakfast
08:00 AM Welcome and Introduction
08:20 AM Acquisition, Systematic Approach to Interpretation, Normal Variants
9:00 AM Alzheimer’s Disease and
9:45 AM Coffee Break
10:00 AM Epilepsy and Neuro-oncology
10:30 AM Newer Indications and Tracers: Amyloid Imaging
11:00 AM NeuroQ 3.7 Update and use in Clinical Setting
11:45 AM Q&A
12:30 PM Wrap-up
SNMMI Annual Meeting in San Diego, CA
June11, 2016 in San Diego, CA at the SNMMI Annual Meeting
Meeting room TBD, San Diego Convention Center
7:30 AM - 12:30 PM
This course is free for the first 50 who register, afterwhich there will be a $100 fee.
Registration will be accepted online until May 31st, 2016.
This course is made possible through an educational grant from Syntermed, Inc (booth 1321) and DOES NOT provide CME credit for attendees.
Win a copy of Dr. Silverman's book
Expert PET Consult Service.
UCLA provides a PET consult service where customers can send the difficult studies to Dr. Silverman and he will provide a consultation with a report on his interpretation of the study. Many of our current customers have used this service and they are very impressed with the high level of interpretive skills Dr. Silverman offers for interpreting brain PET studies. Through this process they gradually increase their level of interpretive skills and their need for the consultation service is reduced as their skills improve. There is a fee associated with this service.